APNasdaq: ASND
Ascendis Pharma is a Danish biotechnology company developing treatments using its TransCon drug-development platform, which is designed to enable specific therapeutic delivery characteristics. Its programs include endocrine diseases and other serious conditions. The issuer announced an important security-structure change in April 2026: Nasdaq ticker ASND continued, but trading changed from American depositary shares to ordinary shares. This directory records the current security type rather than describing ASND as an ongoing ADS listing.
Denmark
TransCon · long-acting-therapeutics · protein-therapeutics
endocrinology · oncology
Verified: 2026-11-08T23:32:43.961Z
Profile and official sources →AP
TSE: 4503
Astellas Pharma is a Japan-headquartered pharmaceutical company engaged in research, development, manufacturing and commercialization of prescription medicines. Its global operations combine pharmaceutical discovery with clinical development and external research partnerships. The company's therapeutic interests include oncology, transplantation and selected specialty diseases, and its development work spans small molecules and advanced therapeutic technologies. Astellas is based in Tokyo and its shares are listed on the Tokyo Stock Exchange under code 4503.
Japan
small molecules · biologics · cell therapies
oncology · transplant medicine · ophthalmology
Verified: 2026-11-08T23:32:43.961Z
Profile and official sources →AP
LSE: AZN Nasdaq Stockholm: AZN NYSE: AZN
AstraZeneca is a United Kingdom-based, science-led pharmaceutical company engaged in discovering, developing and commercializing prescription medicines. Its research and business span oncology, biopharmaceutical medicines and rare diseases, using several treatment technologies and discovery platforms. The company reports its activities through an official corporate and investor website rather than maintaining a fixed product catalogue in this directory. Its investor FAQ confirms the AZN symbol across the London Stock Exchange, Nasdaq Stockholm and New York Stock Exchange, which are securities of the same corporate issuer.
United Kingdom
small-molecule · biologics · oncology-therapeutics
oncology · cardiovascular · respiratory · immunology · rare-diseases
Verified: 2026-11-08T23:32:43.961Z
Profile and official sources →ATNasdaq: AXSM
Axsome Therapeutics is a U.S. biopharmaceutical company developing and commercializing medicines for central nervous system disorders. Its research focuses on pharmacological interventions for neurological and psychiatric conditions, supported by clinical development and commercialization operations. The company's therapeutic interests include disorders affecting mood, cognition, sleep and related neural functions. Axsome is headquartered in New York and its shares are listed on Nasdaq under AXSM. Its work spans the identification of treatment approaches, clinical assessment of therapies and delivery of medicines to patients with neurological or psychiatric needs. This combination of research and commercial capabilities defines its biopharmaceutical operating model.
United States
CNS pharmacology · small molecules
psychiatry · neurology · sleep disorders
Verified: 2026-11-08T23:28:08.692Z
Profile and official sources →BT
Nasdaq Global Select Market: BEAM
Beam Therapeutics is a United States biotechnology company developing precision genetic medicines using base editing technology. Base editing aims to make targeted changes to DNA without relying on the same double stranded cutting mechanism used by some other gene editing approaches. Its development work includes serious inherited diseases, including conditions affecting blood and liver metabolism. Founded in 2017, Beam has its headquarters in Cambridge, Massachusetts, and manufacturing operations in North Carolina. The company publishes official investor disclosures and clinical updates through its website.
United States
base editing · gene editing
hematology · genetic diseases · metabolic diseases
Verified: 2026-11-08T23:27:06.759Z
Profile and official sources →BKSSE STAR: 688687
Beijing Kawin Technology Share-Holding is a China-based biopharmaceutical developer working on treatments for viral and immune-related diseases. Its corporate description identifies an innovative drug-discovery and development focus supported by internal research and pharmaceutical-development capabilities. The Shanghai Stock Exchange STAR Market company page corroborates the issuer and its stock code 688687, while the official company website describes its research platforms and corporate history. Its drug-development programs focus on antiviral and immunology-related therapeutic approaches.
China
biologics · antiviral-medicines · immunology
viral-diseases · immune-diseases
Verified: 2026-11-08T23:32:43.961Z
Profile and official sources →BM
Nasdaq: ONC HKEX: 06160 SSE STAR: 688235
BeOne Medicines develops and commercializes cancer treatments, combining internal discovery with clinical development and global commercialization. The company works across hematologic malignancies and solid tumors and uses a portfolio of therapeutic approaches rather than a single modality. Its official annual report identifies the same issuer across Nasdaq, Hong Kong and Shanghai listings; these securities must be stored under one company identity, not as separate companies. Its therapeutic development spans targeted oncology medicines and biologic treatment approaches.
Switzerland
oncology · small-molecule · biologics
oncology
Verified: 2026-11-08T23:32:43.961Z
Profile and official sources →BPSZSE: 300558
Betta Pharmaceuticals is a China-based innovative pharmaceutical company headquartered in Hangzhou, Zhejiang. Its operations span research, development, manufacturing and commercialization of prescription therapeutics, with strong historical emphasis on targeted cancer treatments. The company also pursues additional discovery technologies and external research collaborations to address unmet medical needs. Betta is listed on the Shenzhen Stock Exchange under security code 300558. Its drug development activities include small-molecule medicines and selected biologic collaborations.
China
targeted small molecules · antibody collaborations · protein degraders
oncology · ophthalmology
Verified: 2026-11-08T23:32:43.961Z
Profile and official sources →BSSSE STAR: 688177
Bio-Thera Solutions is a China-based biopharmaceutical company developing innovative biologic therapies alongside biosimilar medicines. Its scientific work includes antibody therapeutics and other protein-based treatment approaches for serious diseases. The company emphasizes oncology, autoimmune diseases, cardiovascular conditions and selected additional therapeutic areas. Bio-Thera operates from Guangzhou, China, and its shares trade on the Shanghai Stock Exchange STAR Market under code 688177. Its inclusion reflects proprietary therapeutic research and development, not merely biosimilar distribution or contract manufacturing.
China
antibody therapeutics · biologics · biosimilars
oncology · autoimmune disorders · cardiovascular disease
Verified: 2026-11-08T23:32:43.961Z
Profile and official sources →BPNasdaq: BCRX
BioCryst Pharmaceuticals is a U.S. biotechnology company focused on developing and commercializing targeted medicines for rare diseases. Its scientific capabilities emphasize small-molecule discovery and pharmacological approaches selected for specific disease mechanisms. BioCryst is particularly associated with hereditary angioedema and maintains research interests in additional rare conditions. The company operates from Research Triangle Park, North Carolina, and its common shares are listed on Nasdaq under BCRX. BioCryst combines medicinal chemistry and biological research with development and commercialization capabilities. Its focus on rare diseases shapes its approach to therapeutic discovery, clinical development and interactions with specialized patient communities.
United States
structure-guided small molecules · oral therapeutics
rare diseases · hereditary angioedema
Verified: 2026-11-08T23:28:08.692Z
Profile and official sources →BP
SSE STAR: 688796 HKEX: 02315
Biocytogen is a Beijing-headquartered biotechnology company developing platforms and therapeutic antibody assets for drug discovery and collaborative development. Its RenMice and related antibody technologies support fully human antibodies, multispecific formats and antibody-drug conjugate programs. The business also supplies research models and preclinical services, but its disclosed agreements include therapeutic antibody co-development and out-licensing, so it should not be categorized as a pure contract research provider. Biocytogen has public share listings on the Shanghai Stock Exchange STAR Market and the Hong Kong Stock Exchange.
China
fully human antibody discovery · bispecific antibodies · antibody-drug conjugates
oncology · immunology
Verified: 2026-11-08T23:27:06.759Z
Profile and official sources →BI
Nasdaq: BIIB
Biogen is a U.S. biotechnology company engaged in the research, development and commercialization of therapies for serious neurological and related diseases. Its research activities span several medicinal modalities, including biologics and other targeted approaches, supported by clinical-development and commercial capabilities. The company is headquartered in Cambridge, Massachusetts, and its shares trade on Nasdaq under BIIB. Biogen has a long-standing focus on neuroscience, while its clinical and commercial activities also extend into immunology and selected rare diseases.
United States
biologics · neuroscience therapeutics
neurology · immunology · rare diseases
Verified: 2026-11-08T23:27:06.759Z
Profile and official sources →BL
NYSE: BHVN
Biohaven is a clinical-stage biopharmaceutical company developing medicines for a range of neurological, immunological and oncological conditions. Its research includes extracellular protein degradation, other targeted therapeutics and selected antibody-drug conjugate programs. The company maintains research and development activities intended to translate disease mechanisms into drug candidates for rare and more common disorders. Biohaven is listed on the New York Stock Exchange under BHVN and has its corporate presence in New Haven, Connecticut. This concise entry identifies the company and its broad platform and therapeutic areas.
United States
extracellular protein degradation · targeted small molecules · ADC
neurology · immunology · oncology · rare diseases
Verified: 2026-11-08T23:32:43.961Z
Profile and official sources →BPNasdaq: BMRN
BioMarin Pharmaceutical is a U.S. biotechnology company focused on medicines for rare and genetically defined conditions. It develops, manufactures and commercializes therapies informed by genetic and disease biology, including enzyme-based and other targeted treatment approaches. The company is based in San Rafael, California, and its shares are traded on Nasdaq under BMRN. BioMarin's long-term focus includes skeletal and metabolic conditions as well as other rare disorders where specialized drug development and manufacturing capabilities are important.
United States
genetic medicines · enzyme therapies · targeted therapeutics
rare genetic diseases · skeletal conditions · metabolic disorders
Verified: 2026-11-08T23:27:06.759Z
Profile and official sources →BS
Nasdaq: BNTX
BioNTech is a Germany-based biotechnology company focused on immunotherapies and other innovative treatments. Its research includes messenger RNA technologies, engineered immune approaches and additional modalities intended for cancer and infectious diseases. The company combines internal discovery and clinical development with manufacturing capabilities and external research collaborations. BioNTech maintains investor relations materials for its Nasdaq-listed securities and publishes updates about therapeutic and vaccine development on its official website. Its platform research connects genetic medicines with oncology and infectious disease applications.
Germany
mRNA therapeutics · immunotherapies
oncology · infectious disease
Verified: 2026-11-08T23:32:43.961Z
Profile and official sources →BS
NYSE: BMY
Bristol Myers Squibb is a U.S. biopharmaceutical company that discovers, develops, manufactures and commercializes prescription medicines. Its therapeutic platforms include small-molecule drugs, biologic medicines and cell therapies, supported by internal research and external collaborations. Key areas of focus include oncology, immunology and cardiovascular disease. The company's common shares trade on the New York Stock Exchange under BMY. As a global pharmaceutical developer, it operates across multiple stages of research, clinical evaluation and commercial supply.
United States
small molecules · biologics · cell therapies
oncology · immunology · cardiovascular
Verified: 2026-11-08T23:27:06.759Z
Profile and official sources →CT
Nasdaq: CCCC
C4 Therapeutics is a U.S. clinical-stage biotechnology company developing small-molecule medicines based on targeted protein degradation. Its platform is designed to identify molecules capable of directing selected disease-associated proteins toward cellular degradation mechanisms. The company primarily works in oncology, including hematologic malignancies, and seeks to apply degradation science to well-defined biological targets. C4 Therapeutics is headquartered in Watertown, Massachusetts, with shares listed on Nasdaq under CCCC. Its drug discovery strategy combines molecular design, cellular biology and translational research. The intended therapeutic approach differs from conventional inhibition because it seeks to reduce the abundance of a targeted protein.
United States
targeted protein degradation · small molecules
oncology · hematologic malignancies
Verified: 2026-11-08T23:28:08.692Z
Profile and official sources →CBNasdaq: CABA
Cabaletta Bio is a U.S. biotechnology company developing engineered T-cell therapies for autoimmune diseases. The company's scientific work combines cellular engineering with clinical development intended to alter harmful immune responses. Its research interests span rheumatologic, inflammatory and antibody-mediated autoimmune disorders, rather than concentrating solely on oncology. Cabaletta is headquartered in Philadelphia, Pennsylvania, and its shares trade on Nasdaq under CABA. The technology involves modifying immune cells for therapeutic purposes and assessing their effects in defined patient populations. Cabaletta's focus places it within the broader field of cell-based medicines and immune-system modulation for serious disease.
United States
autologous CAR-T · engineered T cells
autoimmune diseases · rheumatology
Verified: 2026-11-08T23:28:08.692Z
Profile and official sources →CSEuronext Growth Paris: ALCLS Nasdaq: CLLS
Cellectis is a France-based biotechnology developer working on gene-edited cell therapies, including engineered T-cell approaches for cancer treatment. The company applies gene-editing technologies to develop therapeutic products and collaborates with partners in advancing these platforms. Its investor FAQ identifies ordinary shares on Euronext Growth Paris under ALCLS and American-listed securities on Nasdaq under CLLS, representing the same issuer across markets. A brief identity and technology overview is retained here, while clinical-program timing and partnership economics are left to its official investor and pipeline pages.
France
gene-editing · cell-therapy · CAR-T
oncology
Verified: 2026-11-08T23:32:43.961Z
Profile and official sources →CIKOSPI: 068270
Celltrion is a South Korean biopharmaceutical company engaged in biologic medicine development, manufacture and commercialization. Its operations include antibody therapeutics and biosimilars, with ongoing pharmaceutical research relevant to autoimmune diseases, oncology and other inflammatory conditions. As a large biologics developer, Celltrion integrates analytical, process and clinical capabilities with global marketing partnerships. The company is listed on the KOSPI market under code 068270 and is based in Incheon, South Korea. This directory represents the listed pharmaceutical issuer rather than treating individual subsidiary brands or distribution arrangements as separate issuers.
South Korea
antibody biologics · biosimilars · therapeutic development
autoimmune diseases · oncology · inflammatory disorders
Verified: 2026-11-08T23:32:43.961Z
Profile and official sources →CKSZSE: 002773
Chengdu Kanghong Pharmaceutical Group is a listed Chinese pharmaceutical company engaged in the research, development, manufacture and sale of medicines. Its business includes biologic therapies, conventional small-molecule pharmaceutical products and traditional Chinese medicine activities. The company conducts innovative therapeutic research in ophthalmology, neurology and selected oncology areas while also operating established commercial medicine businesses. Kanghong is headquartered in Chengdu, Sichuan, and trades on the Shenzhen Stock Exchange under code 002773. Product-specific claims, regulatory changes and scientific updates are maintained through official company and exchange announcements.
China
biologics · small molecules · traditional Chinese medicines
ophthalmology · central nervous system · oncology
Verified: 2026-11-08T23:32:43.961Z
Profile and official sources →CZSZSE: 300122
Chongqing Zhifei Biological Products is a Chinese listed vaccine and biopharmaceutical developer engaged in vaccine research, development, manufacturing and commercialization. Its scientific activities include recombinant and other vaccine technologies, with work aimed at prevention of infectious diseases. The company combines proprietary development with external collaborations and licensed vaccine commercialization, requiring its original R&D activity to be distinguished from distribution-only operations. Zhifei is based in Chongqing, China, and its shares trade on the Shenzhen Stock Exchange under security code 300122.
China
vaccine research · recombinant proteins · mRNA vaccines
infectious diseases · preventive vaccines
Verified: 2026-11-08T23:32:43.961Z
Profile and official sources →CP
TSE: 4519
Chugai Pharmaceutical is a Japan-based research-driven pharmaceutical company developing and commercializing medicines, particularly in areas requiring specialized biological and molecular approaches. Its R&D capabilities include therapeutic antibodies and small molecules across oncology, immunology, hematology and additional specialty disease areas. Chugai is headquartered in Tokyo and its shares trade on the Tokyo Stock Exchange under 4519. The company is affiliated with the Roche group while remaining a separately listed issuer, so its securities should not be merged into Roche's record.
Japan
engineered antibodies · small molecules · biologics
oncology · immunology · hematology · neuroscience
Verified: 2026-11-08T23:32:43.961Z
Profile and official sources →CTNasdaq: CRSP
CRISPR Therapeutics is a Swiss-incorporated biotechnology company developing medicines based on gene editing, including edited cell therapies and other genetic approaches. It uses CRISPR technology to investigate treatments for serious diseases, working across research, clinical development and commercialization partnerships. The corporate investor FAQ identifies Zug as its headquarters and Nasdaq ticker CRSP. Its official website and regulatory filings provide current information on its technologies, commercial arrangements and development programs. Genetic medicine and edited-cell technologies form the core of its therapeutic research.
Switzerland
CRISPR-Cas9 · gene-editing · cell-therapy
hematology · genetic-diseases
Verified: 2026-11-08T23:32:43.961Z
Profile and official sources → 